文献速递乳腺癌放疗放疗物理与技术

FLASH放疗在三阴性乳腺癌小鼠模型中诱导独特免疫转录组谱

FLASH radiotherapy induces unique immunotranscriptomic profiles compared to conventional dose-rate radiotherapy, despite identical immune infiltration and antitumor efficacy in a murine model of triple-negative breast cancer.
PubMed 文献 · Radiother Oncol · 2026-04-28

该研究在三阴性乳腺癌小鼠模型中比较FLASH-RT与常规剂量率放疗(CONV-RT),发现两者在延迟肿瘤生长和免疫细胞浸润方面等效,但FLASH-RT在照射后24小时显著保留趋化因子和干扰素信号相关基因表达,而CONV-RT下调这些基因,提示两种放疗模式存在不同的免疫调节机制。

要点

  • FLASH-RT与CONV-RT在延迟三阴性乳腺癌小鼠肿瘤生长方面等效。
  • FLASH-RT在24小时保留CXCL9/10/11及干扰素α/γ信号相关基因表达。
  • 两种放疗模式在免疫细胞浸润上无差异,但转录组谱不同。

核心结论

  • FLASH-RT与CONV-RT在延迟小鼠三阴性乳腺癌生长和调节免疫应答方面同等有效,但转录组分析揭示不同的免疫调节谱。

研究设计与样本

  • 使用皮下和原位4T1及MDA-MB-231小鼠三阴性乳腺癌模型,雌性BALB/c或Swiss裸鼠接受单次(14或20 Gy)或分次(5×5.2或10×3 Gy)CONV-RT(0.2 Gy/s)或FLASH-RT(5-5.79×10⁶ Gy/s)。

主要发现

  • 所有方案中FLASH与CONV-RT在延迟肿瘤生长方面显示等效性。
  • 照射后24小时,FLASH-RT显著保留趋化因子表达(NES=2.516),包括对T细胞功能关键的CXCL9、10和11。
  • FLASH-RT通过ISGF3复合物保留干扰素α和γ信号(NES=2.998;3.235),导致干扰素刺激基因表达。
  • CONV-RT下调这些基因,但组织学和流式细胞术显示两种模式间免疫细胞浸润无差异。
  • 作者假设FLASH-RT保留I型和II型干扰素负调控因子(NES分别为2.108和1.784)以及炎症负调控因子(NES=1.88,包括PD-L1和IL18BP)的表达可能解释此差异。

临床怎么用

  • FLASH-RT在保持抗肿瘤疗效的同时可能保留有利于T细胞功能的免疫信号,但需进一步研究其临床转化价值。

局限性

  • 研究仅在小鼠三阴性乳腺癌模型中进行,结论需在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triple-negative breast cancer (TNBC) still poses an important clinical challenge due to its aggressiveness, notwithstanding the increasing amount of treatment options. While radiation therapy (RT) is important for TNBC management, dose-limiting side effects limit its efficacy. FLASH-RT, delivered with ultra-high dose rates, has shown anti-tumour effects comparable to conventional dose rate RT (CONV-RT) but with reduced normal tissue side effects, offering the potential of dose escalation to treat aggressive tumour subtypes such as TNBC. METHODS: In this study, we investigated TNBC responses to FLASH-RT across gene transcription, immune infiltration, and anti-tumour efficacy. Using subcutaneous and orthotopic 4 T1 and MDA-MB-231 murine TNBC models, female BALB/c or Swiss nude mice received single (14 or 20 Gy) or fractionated (5 × 5.2 or 10 × 3 Gy) doses of either CONV-RT (0.2 Gy/s) or FLASH-RT (5-5.79 × 10⁶ Gy/s). Tumour growth was monitored, and 4 T1 tumours were collected at 24 h, 5 days, and 2 weeks post-irradiation for histology, flow cytometry, and bulk RNA sequencing. RESULTS: All regimens demonstrated iso-efficacy between FLASH and CONV-RT in delaying tumour growth. RNA sequencing revealed that, 24 h post-irradiation, FLASH-RT significantly preserved expression of chemokines (NES = 2.516), including CXCL9, 10 and 11 which are critical for T cell function. Additionally, FLASH-RT retained interferon alpha and gamma signalling (NES = 2.998; 3.235) via the ISGF3 complex, resulting in interferon-stimulated genes expression. While CONV-RT downregulated these genes, histology and flow cytometry showed no differences in immune cell infiltration between modalities. We hypothesize that FLASH-RT's conserved expression of negative regulators of interferon type I and II (NES = 2.108 and 1.784 respectively), but also negative regulators of inflammation (NES = 1.88), including PD-L1 and IL18BP, may underlie this discrepancy. CONCLUSIONS: In summary, while FLASH-RT and CONV-RT are equally effective in delaying tumour growth and modulating the immune response in murine TNBC, transcriptomic analysis uncovered distinct immunomodulatory profiles, suggesting nuanced mechanisms that warrant further investigation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Arrigo A, Brants L, Kramp L, et al. FLASH radiotherapy induces unique immunotranscriptomic profiles compared to conventional dose-rate radiotherapy, despite identical immune infiltration and antitumor efficacy in a murine model of triple-negative breast cancer. Radiother Oncol. 2026. PMID: 42061755. doi:10.1016/j.radonc.2026.111548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。